<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">TENOFOVIR DISOPROXIL FUMARATE</span><br/>(ten-o-fo'vir di-so-prox'il fum'a-rate)<br/><span class="topboxtradename">Viread<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antiretroviral agent</span>; <span class="classification">nucleoside reverse transcriptase inhibitor (nrti)</span><br/><b>Prototype: </b>Zidovudine<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>300 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Tenofovir is a potent inhibitor of retroviruses, including HIV-1. It may be active against nucleoside-resistant HIV strains.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>The active form of tenofovir persists in HIV-infected cells for prolonged periods, thus, it results in sustained inhibition
         of HIV replication. It reduces the viral load (plasma HIV-RNA), and CD4 counts. It reduces the viral load (plasma HIV-RNA)
         of the patient.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>In combination with other antiretrovirals for the treatment of HIV.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to tenofovir; hepatitis; lactic acidosis; concurrent administration of nephrotoxic agents, renal failure;
         lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Hepatic dysfunction, alcoholism; renal impairment; obesity; children, pregnancy (category B).</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">HIV Infection</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 300 mg once daily with meal<br/><br/><span class="impairmenttitle">Renal Insufficiency</span><br/>Cl<sub>cr</sub> <br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give at the same time each day with a meal.</li>
<li>Give 2 h before or 1 h after didanosine (if ordered concurrently).</li>
<li>Store at room temperature; excursions to 15°30° C (59°80° F) are permitted.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Asthenia. <span class="typehead">CNS:</span> Headache. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea,</span> vomiting, diarrhea, flatulence, abdominal pain, anorexia. <span class="typehead">Hematologic:</span> Neutropenia. <span class="typehead">Metabolic:</span> Increased <span class="speceff-common">creatine kinase,</span> AST, ALT, serum amylase, triglycerides, serum glucose. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May increase <b>didanosine</b> toxicity; <b>acyclovir,</b>
<b>amphotericin B,</b>
<b>cidofovir,</b>
<b>foscarnet,</b>
<b>ganciclovir,</b>
<b>probenecid,</b>
<b>valacyclovir,</b>
<b>valganciclovir</b> may increase tenofovir toxicity by decreasing its renal elimination. <span class="typehead">Food:</span> Food increases absorption. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Bioavailability 25% fasting, 40% with high fat meal. <span class="typehead">Peak:</span> 1 h. <span class="typehead">Distribution:</span> Metabolism: Not metabolized by CYP450 enzyme system. <span class="typehead">Elimination:</span> Renally eliminated. <span class="typehead">Half-Life:</span> 1114 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Monitor baseline and periodic renal function and LFTs; monitor periodically serum electrolytes, and ABGs if lactic
            acidosis is suspected.
         </li>
<li>Monitor for S&amp;S of bone abnormalities (e.g., bone pain, stress fractures).</li>
<li>Monitor closely patients receiving other nephrotoxic agents for changes in serum creatinine and phosphorus. Withhold drug
            and notify physician for creatinine clearance 
         </li><li>Withhold drug and notify physician if patient develops clinical or lab findings suggestive of lactic acidosis or pronounced
            hepatotoxicity (e.g., hepatomegaly and steatosis even in the absence of marked transaminase elevations).
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Take this drug exactly as prescribed. Do not miss any doses. If you miss a dose, take it as soon as possible and then take
            your next dose at its regular time. If it is almost time for your next dose, do not take the missed dose. Wait and take the
            next dose at the regular time. Do not double the next dose.
         </li>
<li>Report any of the following to physician: unexplained anorexia, nausea, vomiting, abdominal pain, fatigue, dark urine.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>